Results of a survey of small-animal practitioners on the perceived clinical efficacy and safety of an oral nutraceutical.
A mail survey of 3080 practitioners from two sampling frames was used to determine the perceived clinical efficacy and safety of an oral nutraceutical for the treatment of degenerative joint disease (DJD) in small animals. Overall response rate was 82%, of which 64% reported that they were recommending the oral nutraceutical to their clients. There was a high variability reported between the severity of DJD and response to treatment. Sixty-eight percent of practitioners reported lame dogs older than five years to be the most responsive to treatment. Most practitioners (83%) believed response to treatment with the studied product occurred within four weeks. Practitioners using the product rated the clinical efficacy of the product to be either 'good' or 'excellent' in improving mobility, alleviating pain and improving attitude in the majority of the treated animals. No practitioner reported a worsening of pain, mobility or attitude. Self-reported adverse effects were 2% (the most common was gastrointestinal upset). The results of this survey indicated that perceived clinical efficacy of the studied nutraceutical in the treatment of DJD was regarded to be 'good' or 'excellent' by most of the practitioners who use this product and was considered to be safe with minimal side effects. This provides additional information on the product for use in planning future clinical trials.